Last reviewed · How we verify
TAA-Specific CTLs
At a glance
| Generic name | TAA-Specific CTLs |
|---|---|
| Also known as | Tumor Associated Antigen-Specific Cytotoxic T-Lymphocytes |
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma (PHASE1)
- TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (PHASE2)
- Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (PHASE1)
- (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). (PHASE1)
- Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE1, PHASE2)
- TAA-Specific CTLS for Solid Tumors (TACTASOM) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAA-Specific CTLs CI brief — competitive landscape report
- TAA-Specific CTLs updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI